Phase 3 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be 18 years of age or older
• You must have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample
• Your cancer must be locally advanced and not able to be removed by surgery, as determined by medical guidelines and a specialist team review
• You must have received 4 to 6 months of active chemotherapy (not counting breaks) using one of these regimens: FOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel — switching between these for side effect reasons is allowed, but not because the cancer got worse
• You must sign up for the study within 45 days of your last chemotherapy cycle
• You must have had body scans (such as CT or MRI) done before you started chemotherapy, for staging purposes
• Your general health and ability to carry out daily activities must meet a certain minimum level (confirm with trial site)
• Certain blood test results (liver enzymes and a tumor marker called CA19-9) must fall within required ranges before and after chemotherapy — the exact values will be checked by the trial team
• Your most recent scans after chemotherapy must show that the cancer has at least stayed stable and not grown or spread
• If you have HIV, you must be on effective treatment with an undetectable virus level within the last 6 months
• Your heart function must be at a satisfactory level based on a standard heart classification scale (confirm with trial site)

Who may not be able to join:

• People who are pregnant or currently breastfeeding
• People who have active ulcers in the stomach or the first part of the small intestine (duodenum)
• People whose tumor is directly growing into the bowel or stomach
• People who have had radiation treatment to the same area of the body where the cancer is located (prior radiation to other unrelated body areas may be acceptable — confirm with trial site)
• People who were hospitalised primarily due to a heart problem in the last 6 months
• People with more severe heart function problems (classified as NYHA Class III or IV — confirm with trial site)
• People whose CA19-9 tumor marker levels have not dropped enough after chemotherapy (the specific required decrease will be assessed by the trial team)

Important: Always verify eligibility with the trial site directly before applying.